Cargando…
Survival of pancreatic cancer cells lacking KRAS function
Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. H...
Autores principales: | Muzumdar, Mandar Deepak, Chen, Pan-Yu, Dorans, Kimberly Judith, Chung, Katherine Minjee, Bhutkar, Arjun, Hong, Erin, Noll, Elisa M., Sprick, Martin R., Trumpp, Andreas, Jacks, Tyler |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653666/ https://www.ncbi.nlm.nih.gov/pubmed/29061961 http://dx.doi.org/10.1038/s41467-017-00942-5 |
Ejemplares similares
-
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
por: Muzumdar, Mandar Deepak, et al.
Publicado: (2016) -
Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma
por: Dayton, Talya L., et al.
Publicado: (2018) -
CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer
por: Ng, Sheng Rong, et al.
Publicado: (2020) -
Decoding the obesity–cancer connection: lessons from preclinical models of pancreatic adenocarcinoma
por: Ruiz, Christian F, et al.
Publicado: (2023) -
Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1–3 family
por: JnBaptiste, Courtney K., et al.
Publicado: (2017)